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Abstract  
Objective: We aimed to characterize dementia with Lewy bodies (DLB) by the 
quantitative MRI parameters of longitudinal relaxation time (qT1) and 
transverse relaxation time (qT2). These parameters reflect potential 
pathological changes in tissue microstructures, which may be detectable 
noninvasively in brain areas without evident atrophy, so may have potential 
value in revealing the early neuropathological changes in DLB. 
 
Methods: We conducted a cross-sectional study of subjects with DLB (N = 35) 
and similarly aged control participants  (N = 35). All subjects underwent a 
detailed clinical and neuropsychological assessment and structural and 
quantitative 3T MRI. Quantitative MRI maps were obtained using relaxation 
time mapping methods. Statistical analysis was performed on gray matter qT1 
and qT2 values. 
 
Results: We found significant alterations of quantitative parameters in DLB 
compared to controls. In particular, qT1 decreases in bilateral temporal lobes, 
right parietal lobes, basal ganglia including left putamen, left caudate nucleus 
and left amygadala, and left hippocampus / parahippocampus; qT2 decreases 
in left putamen and increases in left precuneus. These regions showed only 
partial overlap with areas where grey matter loss was found, making atrophy 
an unlikely explanation for our results. 
 
Conclusions: Our findings support that DLB is predominantly associated with 
changes in posterior regions, such as visual association areas, and 
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subcortical structures, and that qT1 and qT2 measurement can detect subtle 
changes not seen on structural volumetric imaging. Hence, quantitative MRI 
may compliment other imaging techniques in detecting early changes in DLB 
and in understanding neurobiological changes associated with the disorder. 
 
(248 words) 
 
Keywords 
dementia, Lewy body disease, quantitative MRI, neuroimaging, VBQ 
 
 4 
Introduction 
Dementia with Lewy bodies (DLB) is the second commonest subtype of 
degenerative dementia in older people after Alzheimer disease (AD) [1]. It 
shares common clinical and neuropsychological features with other subtypes 
of dementia such as AD and Parkinson’s disease dementia (PDD), but has a 
distinctive pattern of pathological changes [2,3]. In comparison to AD, DLB 
has been shown to have less severe atrophy than AD, but with a more diffuse 
and less focal pattern [4,5], with relatively preserved medial temporal lobes 
[2,6,7,8]. One of the most notable characteristics of DLB is visuo-spatial 
deficit, and imaging studies using mostly PET/SPECT in DLB have highlighted 
the involvement of occipital [9,10,11], temporoparietal [1,3,12] and subcortical 
areas [13,14,15]. These characteristics of functional rather than structural 
changes make conventional volumetric MR technique insufficient to fully 
describe DLB. 
 
There is evidence that other MR parameters, for example, longitudinal 
relaxation time (qT1) and transverse relaxation time (qT2), may be more 
sensitive to changes in tissue microstructure, biochemical environment and 
integrity than macrostructural volume reductions [16]. For example, significant 
variations in these parameters were found during aging [17] and underlying 
physiological processes at the cellular and molecular level demonstrated by 
postmortem histological investigations in transgenic 5xFAD mouse animal 
model of AD [18]. We therefore hypothesize that quantitative qT1 and qT2 
mapping is able to differentiate DLB from healthy controls and indirectly reveal 
neurobiological abnormalities of DLB at subvoxel scale. 
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In this study, we evaluated maps of quantitative modulation of qT1 and qT2 in 
grey matter, and compared MRI parameters between the DLB and the 
similarly aged control groups using the voxel-based quantification (VBQ) 
approach [17]. The main aims of this study were to characterize the 
neuropathology in DLB based on high-resolution quantitative MR parameter 
images, and explore their clinical relevance. 
 
Material and methods 
Subject recruitment and assessment 
Thirty-five individuals with probable DLB were recruited from a community-
dwelling population of patients referred to local old age psychiatry, geriatric 
medicine, or neurology services as previously described [2]. Thirty-five 
controls were recruited from among spouses and friends of the subjects with 
dementia or from advertisements in local community newsletters. All 
participants underwent clinical and neuropsychological evaluations with 
diagnostic procedures previously employed by our group [3]. The research 
was approved by the local ethics committee. All participants (or, where 
appropriate, their nearest relative) provided written informed consent. 
 
Assessment of global cognitive measures in all participants involved use of 
the Cambridge Cognitive Examination (CAMCOG), which incorporates the 
Mini-Mental State Examination (MMSE) [19]. Motor Parkinsonism was 
assessed with the Unified Parkinson’s Disease Rating Scale Part III (UPDRS-
III) [20]. For patients with dementia, neuropsychiatric features were assessed 
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with the Neuropsychiatric Inventory (NPI) [21], and function was assessed 
with the Bristol Activities of Daily Living (Bristol ADL) [22].  
 
MRI data acquisition  
Participants underwent MRI scanning on a 3T Philips Achieva MRI system 
with an 8-channel receiver head coil. Structural images were acquired using a 
T1 weighted volumetric sequence (3D MPRAGE, sagittal acquisition aligned 
with the AC-PC line, 1mm isotropic resolution, matrix 240×240×180, 
TR=9.6ms, TE=4.6ms, flip angle=8o, SENSE factor 2). Quantitative images 
were acquired using a fast quantitative T1 measurement based on a custom 
inversion recovery prepared EPI sequence [23] (axial slices, 2mm isotropic 
resolution, matrix 128×128×72, TR=15s, TE=24ms, inversion time TIR=0.25 
to 2.5s in 12 uniform steps); and a fast quantitative multi-echo T2 
measurement based on a Gradient and Spin Echo Imaging sequence (2mm 
isotropic resolution, matrix 128×128×72, TR=4.7s, 8 spin echoes at 20ms 
spacing, EPI factor 5). Please see Supplementary Information E1 for a 
validation of quantitative imaging methodology. In addition, a B0 field-map 
using a dual echo 3D GRE (2mm isotropic resolution, matrix 128×128×72, 
TR=27ms, TE=2.6/6.1ms) was acquired. 
 
Statistical Tests of Demographic, clinical, and cognitive measures. 
Group characteristics were evaluated with Statistical Toolbox of Matlab 
(www.mathworks.co.uk/products/statistics). Differences in demographic and 
clinical data were assessed with use of either t-tests for continuous variables 
or χ2 tests for categorical measures. For each test statistic, a probability value 
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of p<0.05 was regarded as significant.  
 
Voxel-based quantification 
MRI data processing was performed in a combined FSL 
(fsl.fmrib.ox.ac.uk/fsl/fslwiki) and SPM (www.fil.ion.ucl.ac.uk/spm) based on 
the previously validated voxel-based quantification (VBQ) procedure [17].  
Grey matter volume changes but not other data on this cohort has been 
previously published [2] and we undertook a similar analysis here to 
determine whether qT1 and qT2 changes were associated with grey matter 
atrophy (see Supplementary Information E2). Volumetric structural T1 
weighted images were firstly segmented using Gaussian mixture model 
implemented in the VBM toolbox [24], and brain tissues were classified into 
grey matter (GM), white matter (WM) and Cerebrospinal fluid (CSF). GM 
probability maps were non-linearly normalized to standard MNI space 
(www.mni.mcgill.ca) using the diffeomorphic registration algorithm (DARTEL) 
[24] in SPM. Raw qT1 and qT2 imaging datasets were corrected for field 
inhomogeneities using B0 maps and the PRELUDE/FUGUE algorithm in FSL 
[25]. Then, the bias corrected qT1 and qT2 maps were calculated on voxel-
by-voxel basis using non-linear least squares fitting to standard single 
exponential models [16] before further analysis. 
 
In order to minimize the influence of partial volume effect, we used a 
multimodal approach during the preprocessing stages [17]. The qT1 and qT2 
maps were firstly co-registered with the GM probability maps derived from 
structural T1 images, and then masked using the thresholded GM probability 
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maps (at p>0.5) in each participant’s native space. We then transformed the 
GM maps of qT1 and qT2 MRI parameters into standard MNI space using the 
participant-specific diffeomorphic parameters estimated from the previous 
DARTEL procedure. However, we did not apply modulation to these 
quantitative MRI parameters in order to avoid confound of age and disease 
related GM volume changes. Finally, all normalized quantitative qT1 and qT2 
maps were smoothed with an isotropic Gaussian kernel of 6mm full width at 
half maximum. For the qT1 analysis only, images of three participants in the 
DLB group were excluded due to the excessive amount of artifact and 
distortions. 
 
For statistical analysis investigating disease induced regional microstructural 
alterations between the DLB and control groups, we used the General Linear 
Model (GLM) with age and gender as covariates. Then, two-tailed t-tests were 
preformed at each voxel to detect regional difference between the DLB and 
control groups. The false positive rate was controlled using family-wise error 
(FWE) correction for multiple comparisons, and thresholded at p<0.05 at the 
cluster level.  
 
Post-hoc region-of-interest analysis 
To quantify the magnitude of changes in qT1 and qT2, we extracted the 
averaged quantitative MRI values from significant clusters and from two 
regions, which did not show significant changes (bilateral middle occipital 
lobes and bilateral middle prefrontal lobes defined using AAL atlas [26]). Here, 
we used the unsmoothed maps in order to preserve the original values of the 
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MR parameters. These plots are not for statistical inference but illustrating the 
underlying qT1 and qT2 values. 
 
To explore the clinical relevance of qT1 and qT2, in a post-hoc region-of-
interest (ROI) analysis, we have correlated the averaged quantitative MRI 
values extracted from the significant clusters obtained from the previous 
group comparison with cognitive and clinical measures. These measurements 
included the CAMCOG total score (CAM total), also divided into executive 
function, remote memory (which reflects semantic knowledge), and recent 
memory (which reflects episodic information) sub scores [19], UPDRS, 
MMSE, Bristol ADL, NPI and Geriatric Depression Scale (GDS). Multiple 
comparisons were controlled using Bonferroni correction for the number of 
cognitive and clinical measures. 
 
Results 
Demographic clinical and cognitive measures 
As shown in Table 1, there were no significant differences between DLB and 
control groups for age, sex and educational level. As expected, on all 
cognitive and clinical measures (shown in Table 1) DLB patients scored less 
well that the controls. 
 
Insert Table 1 here 
 
Group difference in longitudinal relaxation time (qT1) 
As shown in Figure 1A and Table 2A, we found a significant decrease 
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(p<0.0001, FWE) in qT1 for the DLB group compared to controls in bilateral 
superior and middle temporal lobes, and right angular gyrus. In addition, there 
was a significant decrease of qT1 in several key subcortical / striatal nuclei 
such as the left amygadala (extending to hippocampus and 
parahippocampus) (p=0.001, FWE), left putamen (p<0.0001, FWE) and left 
caudate (p=0.004, FWE). There was also a marginally significant reduction in 
qT1 in the right hippocampus, right putamen and right caudate (not shown). 
The actual averaged qT1 values from the significant clusters are shown as 
bar graphs in Figure 1 illustrating the group differences although qT1 in the 
two control regions in frontal and occipital lobes were not different between 
groups; see Figure 1B. 
 
Insert Table 2 here 
 
Insert Figure 1 here 
 
Group difference in transverse relaxation time (qT2) 
For the transverse relaxation time (qT2), the DLB group showed a significant 
reduction in left putamen (p=0.002, FWE); see Figure 2A and Table 2B.  
Moreover, there was also a marginally significant reduction in qT2 in the right 
putamen  (not shown). We also found a significant increase in qT2 for the 
DLB subjects compared with controls in the left precuneus (p=0.021, FWE); 
see Figure 2B and Table 2C. Similar to qT1, qT2 in both clusters except for 
the two control regions were different between groups (see bar graphs in 
Figure 2).  
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Insert Figure 2 here 
Correlation between cognitive / clinical measures and quantitative MRI 
A significant correlation was found between the CAMCOG executive function 
score and the qT1 values in left middle temporal lobe (r=0.39, p=0.027) and 
left putamen (r=0.36, p=0.044). In addition, a significant correlation was also 
found between CAMCOG recent memory score and the left hippocampus 
extending to amygdala and parahippocapus (r=0.53, p=0.0018). Finally, a 
significant inverse correlation was found between Geriatric Depression Scale 
and the left middle temporal (r=-0.45, p=0.011) and left putamen (r=-0.42, 
p=0.016). No other significant correlation between cognitive / clinical 
measures and quantitative MRI values was found.  
 
Among the above results, only the correlation between recent memory (but 
not the remote memory) performance and qT1 in left hippocampus survives 
the correction for the multiple comparisons (see Figure 3). This relationship 
was still significant after controlling for age, gender and illness duration as 
covariates. In addition, DLB patients scored significantly lower than controls in 
recent (t(68)=-6.45, p<0.00000001) and to a lesser degree but still 
significantly in remote (t(68)= -4.27, p<0.00001) COMCOG memory tests.  
 
Insert Figure 3 here 
 
Discussion 
The main findings of this study were tissue water environment changes in 
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posterior areas of the cortex and subcortical regions of the brain for DLB. This 
is consistent with previous MRI [2], SPECT [13,27], PET [28,29,30] and DTI 
[3,31] studies implicating these regions as most affected by the disease. In 
particular, we have found alterations in qT1 and qT2 measures in posterior 
parts of the temporoparietal lobes, and in several subcortical regions such as 
amygadala, putamen and caudate nucleus. And most strikingly, the majority 
of these regions do not overlap with where grey matter atrophy was found in 
DLB (see Supplementary Information E3 and E4). This not only makes 
atrophy an unlikely explanation for our findings, but suggests that quantitative 
MRI mapping may compliment other imaging techniques in detecting early 
changes in DLB when none are demonstrable on conventional structural 
imaging. 
 
The significant decrease in T1 relaxation time in the bilateral superior/middle 
temporal lobes and right parietal regions, e.g. angular gyrus, was associated 
with a GM volume reduction. This may be related to the memory and attention 
impairments in DLB. For example, the qT1 value in left hippocampus region 
(composing of amygdala and parahippocampus) was significantly positively 
correlated with episodic memory impairment (i.e. CAMCOG recent memory 
score) but not semantic memory impairment (i.e. CAMCOG remote memory 
score) in DLB. The absence of a significant correlation between semantic 
memory and abnormality in temporal cortex is perhaps due to the weaker 
remote memory deficit in DLB and the relatively more distributed 
representations of semantic knowledge in the brain. The decrease in qT1 at 
left middle temporal and putamen was negatively correlated with the severity 
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of depression symptoms (at uncorrected level). This implies that the reduction 
of qT1 in these brain areas may have specific clinical implications. We have 
also found quantitative MRI parameter (qT2) differences between DLB and 
controls in precuneus, an area that plays important role in visuospatial 
processing. Such abnormality in visual and visual association areas may also 
underpin the clinical and cognitive impairments in patients with DLB, such as 
recurrent visual hallucinations and visuo-perceptual dysfunction. Consistent 
with our finding, decreased qT1 is also associated with the layer specific 
increase in β-amyloid deposition in 5xFAD mice [18].  
 
Despite the significant clinical manifestations of parkinsonism for DLB, most 
previous morphometric studies of DLB using structural MRI did not find 
consistent volume reduction in anatomical areas related to the dopaminergic 
system. On the one hand, FP-CIT SPECT studies using specific imaging 
ligands have reported a substantial 40-50% loss in dopaminergic activity in 
the striatum [27]. On the other hand, Cousins et al [15] have only reported an 
approximately 13% volume reduction in bilateral putamen in DLB compared to 
controls. With the minimal reduction in subcortical volume, previous MRI 
studies on GM volume changes did not fully reflect the notable dopamine 
transporter deficiencies found in DLB.  
 
However, we have identified several subcortical regions in the brain that are 
potentially associated with dopamine functions. In comparison to control 
subjects, the averaged qT1 and qT2 values in putamen were decreased by 
45% and 52% respectively with DLB suggesting that these local tissue 
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alterations may be due to Lewy body related pathology and agreeing with 
findings from FP-CIT SPECT studies [27]. In addition, we have shown that 
qT1 value in left putamen was correlated with executive function deficit in DLB 
(at the uncorrected level). During healthy aging, qT2* (a quantitative MRI 
parameter related to qT2) has also been found to be negatively correlated 
with age in a wide range of brain areas, in particular in bilateral putamen, 
reflecting an increased level of iron [32]. In parkinson’s disease, lower qT2* in 
putamen is also associated with more severe motor symptoms [33]. In 
addition, we have shown that qT1 parameters were decreased in the left 
caudate nucleus by 68% with DLB. This finding is consistent with the volume 
reduction in this area and with the known degeneration of the nigrostriatal 
dopamine pathway associated with DLB. 
 
In terms of determining the possible underlying biophysical interpretation of 
these quantitative MRI parameters, qT1 is predominantly influenced by water 
content but also relates to the degree of myelination [34,35,36]. Both qT1 and 
qT2 are also sensitive to the level of iron (or other paramagnetic ions in the 
tissue) [37,38].  It is difficult to say precisely what causes qT1 or qT2 to 
change since they are affected by a range of processes, e.g. demyelination, 
inflammation, iron, ischemia, edema, and so on. It remains to be seen 
whether changes in quantitative MRI values reflect abnormalities in the local 
tissue environment associated with neurodegenerative diseases in general, or 
whether they may indicate a more specific degenerative process. 
Nonetheless, the potential ability of quantitative MRI in detecting early 
changes of tissue property caused by neurodegenerative disease without 
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evident atrophy is clinically promising. Compared to nuclear imaging and 
structural MRI, quantitative MRI is a new and versatile diagnostic tool in 
investigating neurobiological changes in DLB, with potential for the early 
detection of DLB since it is not only a noninvasive method, but can also 
provide more subtle information on local pathology than morphometric 
measures.  
 
A potential weakness of this approach is the relatively low 2mm isotropic 
resolution compared to the cortical thickness. Other studies have achieved 
finer resolution in healthy controls but at the expense of substantially longer 
times, which are challenging for this patient group [36]. Our scans were 
acquired with scan times of less than 4 minutes each making them acceptable 
in ageing populations. At 2mm resolution there is a potential for partial volume 
effects, particularly with CSF, which can substantially skew quantitative values 
[39]. Such partial volume effects would cause significant increases in qT1 and 
qT2 and would be most evident in regions of cortical atrophy. As our data 
show reduced values and do not coalign with the previously described pattern 
of atrophy in this patient cohort [2] we are confident that these changes reveal 
true disease related, parametric changes in the underlying gray matter (see 
Supplementary Information E5). 
 
Conclusions 
In conclusion, we have shown that quantitative MRI is applicable in both 
understanding the neurobiology of the disease and has the potential in clinical 
diagnosis. Further research should investigate at what stages in the disease 
 16 
qT1 and qT2 changes start to occur, and how they alter with disease 
progression. 
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